A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season
Top Cited Papers
Open Access
- 29 March 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 63 (1) , 21-32
- https://doi.org/10.1093/cid/ciw176
Abstract
Background. The 2014–2015 influenza season was distinguished by an epidemic of antigenically-drifted A(H3N2) viruses and vaccine components identical to 2013–2014. We report 2014–2015 vaccine effectiveness (VE) from Canada and explore contributing agent–host factors. Methods. VE against laboratory-confirmed influenza was derived using a test-negative design among outpatients with influenza-like illness. Sequencing identified amino acid mutations at key antigenic sites of the viral hemagglutinin protein. Results. Overall, 815/1930 (42%) patients tested influenza-positive: 590 (72%) influenza A and 226 (28%) influenza B. Most influenza A viruses with known subtype were A(H3N2) (570/577; 99%); 409/460 (89%) sequenced viruses belonged to genetic clade 3C.2a and 39/460 (8%) to clade 3C.3b. Dominant clade 3C.2a viruses bore the pivotal mutations F159Y (a cluster-transition position) and K160T (a predicted gain of glycosylation) compared to the mismatched clade 3C.1 vaccine. VE against A(H3N2) was −17% (95% confidence interval [CI], −50% to 9%) overall with clade-specific VE of −13% (95% CI, −51% to 15%) for clade 3C.2a but 52% (95% CI, −17% to 80%) for clade 3C.3b. VE against A(H3N2) was 53% (95% CI, 10% to 75%) for patients vaccinated in 2014-2015 only, significantly lower at −32% (95% CI, −75% to 0%) if also vaccinated in 2013–2014 and −54% (95% CI, −108% to −14%) if vaccinated each year since 2012–2013. VE against clade-mismatched B(Yamagata) viruses was 42% (95% CI, 10% to 62%) with less-pronounced reduction from prior vaccination compared to A(H3N2). Conclusions. Variation in the viral genome and negative effects of serial vaccination likely contributed to poor influenza vaccine performance in 2014–2015.Keywords
Funding Information
- Canadian Institutes of Health Research (TPA-90193)
- British Columbia Centre for Disease Control
- Alberta Health and Wellness
- Public Health Ontario
- Ministère de la santé et des services sociaux du Québec
- l'Institut national de santé publique du Québec
- Public Health Agency of Canada
- Canadian Institutes of Health Research
This publication has 39 references indexed in Scilit:
- Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesPublished by Elsevier ,2016
- Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case–Control Study, Europe 2014/15Eurosurveillance, 2016
- Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season resultsEurosurveillance, 2015
- Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015Eurosurveillance, 2015
- Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease RiskPLOS ONE, 2014
- Influenza Vaccine Effectiveness in the Community and the HouseholdClinical Infectious Diseases, 2013
- Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccinesProceedings of the National Academy of Sciences, 2009
- SWISS-MODEL: an automated protein homology-modeling serverNucleic Acids Research, 2003
- Predicting the Evolution of Human Influenza AScience, 1999
- Variable efficacy of repeated annual influenza vaccinationProceedings of the National Academy of Sciences, 1999